TransCode Therapeutics ( (RNAZ) ) has released a notification of late filing.
TransCode Therapeutics, Inc. has announced a delay in filing its Annual Report on Form 10-K (Yearly Report) for the financial period ending December 31, 2024. The delay is primarily due to the need for additional time to incorporate disclosures related to a recent Registered Direct Offering, which involved the issuance of 10,250,000 shares and warrants. The company expects to file the report within the extension period allowed under Rule 12b-25. The Registered Direct Offering and other warrants issued during the year have significantly impacted the company’s financial performance, potentially leading to notable changes in its financial results. The notification was signed by Thomas A. Fitzgerald, the Interim Chief Executive Officer and Chief Financial Officer, who assured ongoing compliance efforts.
More about TransCode Therapeutics
YTD Price Performance: -86.12%
Average Trading Volume: 7,211,431
Technical Sentiment Signal: Buy
Current Market Cap: $11.44M
For detailed information about RNAZ stock, go to TipRanks’ Stock Analysis page.